A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 64
- Population
- ALL · 50 Years
- Duration
- 2026-06-29 to 2028-12-31
- Intervention
- Faricimab Injection [Vabysmo]
- Comparator
- Not reported
- Outcomes measured
- ANG-2 level in aqueous humour (AH) — at Week 20 from baseline; Endothelial ANG-2 level in aqueous humour (AH) — At weeks 4, 12, 20 and 52 from baseline; BCVA measurement — At weeks 20 and 52 from baseline; Subfoveal choroidal thickness — At weeks 20 and 52 from baseline; Central subfield thickness (CST) — At weeks 20 and 52 from baseline; Intraretinal microaneurysms and vessel density of the deep capillary plexus — At weeks 20 and 52 from baseline; Area of peripheral non-perfusion in the retina — At weeks 20 and 52 from baseline; High improvement in vascular stabilization — from baseline at Weeks 20; Complete polyp regression — At weeks 20 and 52 from baseline; Polyp inactivation — At weeks 20 and 52 from baseline; Resolution of central Intraretinal fluid/Subretinal fluid(IRF/SRF) — At weeks 20 and 52 from baseline; Vascular remodeling — At weeks 20 and 52 from baseline; Number of injections per patient — From baseline to Week 52(EOS); Treatment interval — From baseline to Week 52(EOS); Maximum treatment interval — From baseline to Week 52(EOS)
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.